摘要
乳腺导管原位癌(DCIS)被认为是一种可以治愈的早期癌症,其中一些导管原位癌被认为是具有向浸润性导管癌(IDC)发展的潜能。DCIS伴微浸润(DCIS-Mi)被认为是DCIS向IDC发展的过渡阶段,而IDC的治疗、预后复发及生存率与DCIS完全不同,故对DCIS的早期诊治非常有必要。本文主要就乳腺导管原位癌的影像学特征、病理分子生物学标记物及其临床治疗预后的相关性进行综述,旨在从影像学角度认识导管原位癌的生物学行为。
Ductal carcinoma in situ(DCIS)is considered to be a curable early cancer,some of which are considered to have the potential to develop into invasive ductal carcinoma(IDC).DCIS with microinvasion(DCIS-Mi)is considered to be a transitional stage from DCIS to IDC,and the treatment,prognosis,recurrence and survival rate of IDC are completely different from those of DCIS,so it is necessary to diagnose and treat DCIS early.This article reviews the imaging features,pathological molecular biological markers and their correlation with clinical treatment and prognosis of ductal carcinoma in situ,aiming to understand the biological behavior of ductal carcinoma in situ from the perspective of imaging.
作者
王娟娟
成官迅
马捷
WANG Juan-juan;CHENG Guan-xun;MA Jie(Medical College of Shantou University,Shantou 515000,Guangdong,China;Department of Radiology,Shenzhen People's Hospital,Shenzhen 518000,Guangdong,China;Department of Medical Imaging,Shenzhen Hospital,Peking University,Shenzhen 518000,Guangdong,China)
出处
《医学信息》
2022年第16期150-154,共5页
Journal of Medical Information
关键词
乳腺导管原位癌
导管原位癌伴微浸润
浸润性导管癌
Ductal carcinoma in situ
Ductal carcinoma in situ with microinvasion
Invasive ductal carcinoma
